Complix to Present at AACR 2016

Hasselt, April 8, 2016 – Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, announces that its research team will be presenting their most recent data on anti-MCL-1 Alphabodies at the American Association for Cancer Research meeting in New Orleans, April 16-20. Their poster entitled “First-in-class cell penetrating proteins targeting Mcl-1 induce tumor cell apoptosis and inhibition of tumor growth in vivo” will provide insight in the recent progress that the Complix team has achieved in developing cell penetrating Alphabodies (CPABs) that act on an important intracellular cancer target and provoke a therapeutic effect in vivo.

Details of the poster presentation are as follows:

Title of the poster: “First-in-class cell penetrating proteins targeting Mcl-1 induce tumor cell apoptosis and inhibition of tumor growth in vivo”
Poster section: 19, poster# 3850
Time: Tuesday the 19th of April between 1 and 5 PM

About Complix

Complix is a biopharmaceutical company developing a pipeline of novel biotherapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases.
Alphabodies are a revolutionary class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals.

Complix´ current R&D efforts are focused on the development of Cell Penetrating Alphabodies (CPABs) that have demonstrated a unique capacity to enter tumor cells and tissues effectively and selectively modulate intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of cancer.

Complix is also developing Alphabody based bispecifics for the treatment of autoimmune diseases. Its most advanced drug candidate is a bispecific Alphabody-antibody fusion that simultaneously targets two key cytokines in the inflammation cascade, namely TNFα and IL-23.

Complix NV (Belgium) and its affiliate Complix SA (Luxembourg) have established a strong intellectual property position protecting the Alphabody™ platform and its emerging product portfolio through the filing of multiple broad patent applications. Alphabody-based therapeutics are independent of antibody-based patent claims and offer a unique freedom-to-operate position.

Since its founding in 2008 Complix has raised a total of more than €20 million in venture financing, including a €12 million B round in June 2013 and a €7 million Series A equity round in 2010.

Contacts

Complix NV
Dr. Yvonne McGrath, CSO
+32 9 261 69 40
info@complix.com